Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 17k
2 September 2019
E-002597-19
Question for written answer E-002597-19
to the Commission
Rule 138
Pascal Arimont (PPE)

 Subject:  Added value of new medicines and EMA authorisation procedures
 Answer in writing 

A study by scientists at the Institute for Quality and Efficiency in Health Care (IQWiG), published in the British Medical Journal in July this year (https://www.bmj.com/company/newsroom/no-evidence-of-added-benefit-for-most-new-drugs-say-researchers/), shows that, in the case of many newly authorised medicines placed on the German market, there is no evidence of any added benefit compared to standard drugs. In total, the Institute examined 216 medicines which had been newly authorised between 2011 and 2017. 58% of them were found to lack any added value.

Is the Commission aware of the findings and recommendations of this study, and will it draw any conclusions from them for the European Medicines Agency’s authorisation procedures?

Original language of question: DE 
Last updated: 18 September 2019Legal notice